Wedbush Maintains Outperform on Arcus Biosciences, Lowers Price Target to $30

Arcus Biosciences -0.98%

Arcus Biosciences

RCUS

16.12

-0.98%

Wedbush analyst Robert Driscoll maintains Arcus Biosciences (NYSE: RCUS) with a Outperform and lowers the price target from $36 to $30.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via